BG108166A - Imidazo-pyrimidine derivatives as liigands for gaba receptors - Google Patents

Imidazo-pyrimidine derivatives as liigands for gaba receptors

Info

Publication number: BG108166A
Authority: BG; Bulgaria
Prior art keywords: pyrimidine derivatives; liigands; imidazo; substituted; phenyl ring
Prior art date: 2001-03-21

Application number

BG108166A

Other languages

Bulgarian (bg)

English (en)

Inventor

Mark S. Chambers

Simon C. Goodacre

David J. Hallett

Andrew Jennings

Philip Jones

Richard T. Lewis

Kevin W. Moore

Leslie J. Street

Helen J. Szekeres

Original Assignee

Merck Sharp & Dohme Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2003-09-09

Publication date

2004-09-30

2001-03-21 Priority claimed from GB0107134A external-priority patent/GB0107134D0/en

2001-11-21 Priority claimed from GB0127938A external-priority patent/GB0127938D0/en

2003-09-09 Application filed by Merck Sharp & Dohme Limited filed Critical Merck Sharp & Dohme Limited

2004-09-30 Publication of BG108166A publication Critical patent/BG108166A/xx

Links

102000005915 GABA Receptors Human genes 0.000 title 1
108010005551 GABA Receptors Proteins 0.000 title 1
150000005237 imidazopyrimidines Chemical class 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
XKTONDZDILVOOL-UHFFFAOYSA-N 3-phenylimidazo[1,2-a]pyrimidine Chemical class C=1N=C2N=CC=CN2C=1C1=CC=CC=C1 XKTONDZDILVOOL-UHFFFAOYSA-N 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
102000027484 GABAA receptors Human genes 0.000 abstract 1
108091008681 GABAA receptors Proteins 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
230000036461 convulsion Effects 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG108166A 2001-03-21 2003-09-09 Imidazo-pyrimidine derivatives as liigands for gaba receptors BG108166A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0107134A GB0107134D0 (en)	2001-03-21	2001-03-21	Therapeutic agents
GB0127938A GB0127938D0 (en)	2001-11-21	2001-11-21	Therapeutic agents
PCT/GB2002/001351 WO2002074772A1 (fr)	2001-03-21	2002-03-19	Derives d'imidazo-pyrimidine utilises comme ligands pour les recepteurs gaba

Publications (1)

Publication Number	Publication Date
BG108166A true BG108166A (en)	2004-09-30

Family

ID=26245875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108166A BG108166A (en)	2001-03-21	2003-09-09	Imidazo-pyrimidine derivatives as liigands for gaba receptors

Country Status (24)

Country	Link
EP (1)	EP1381606B1 (fr)
JP (1)	JP4409174B2 (fr)
KR (1)	KR20030083001A (fr)
CN (1)	CN1294133C (fr)
AT (1)	ATE299882T1 (fr)
AU (1)	AU2002241138B2 (fr)
BG (1)	BG108166A (fr)
BR (1)	BR0207994A (fr)
CA (1)	CA2461426C (fr)
CZ (1)	CZ20032539A3 (fr)
DE (1)	DE60205101T2 (fr)
EA (1)	EA006234B1 (fr)
EE (1)	EE200300455A (fr)
ES (1)	ES2244752T3 (fr)
HU (1)	HUP0303630A3 (fr)
IL (1)	IL157641A0 (fr)
MX (1)	MXPA03008572A (fr)
NO (1)	NO20034170L (fr)
NZ (1)	NZ527901A (fr)
PE (1)	PE20020970A1 (fr)
PL (1)	PL363804A1 (fr)
SK (1)	SK11672003A3 (fr)
TW (1)	TWI248936B (fr)
WO (2)	WO2002074773A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0117277D0 (en)	2001-07-16	2001-09-05	Merck Sharp & Dohme	Therapeutic agents
GB0128499D0 (en) *	2001-11-28	2002-01-23	Merck Sharp & Dohme	Therapeutic agents
GB0226462D0 (en) *	2002-11-13	2002-12-18	Merck Sharp & Dohme	Therapeutic agents
BRPI0412908A (pt) *	2003-07-25	2006-09-26	Neurogen Corp	composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção ou demência de alzheimer, para potenciar um efeito terapêutico de um agente do cns, para melhorar a memória de curta duração em um paciente, para alterar a atividade de transdução de sinal de receptor gabaa, e para determinar a presença ou ausência de receptor gabaa em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal
HRP20150642T1 (hr)	2006-12-22	2015-08-14	Astex Therapeutics Limited	BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8513276B2 (en)	2006-12-22	2013-08-20	Astex Therapeutics Limited	Imidazo[1,2-a]pyridine compounds for use in treating cancer
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
WO2011047320A2 (fr)	2009-10-16	2011-04-21	Rib-X Pharmaceuticals, Inc.	Composés anti-microbiens et procédés permettant de les fabriquer et de les utiliser
US9216979B2 (en)	2009-10-16	2015-12-22	Melinta Therapeutics, Inc.	Antimicrobial compounds and methods of making and using the same
TW201726630A (zh) *	2009-10-16	2017-08-01	梅林塔療法公司	抗微生物性化合物及其製造與使用方法
US20150374705A1 (en)	2012-02-14	2015-12-31	Shanghai Institues for Biological Sciences	Substances for treatment or relief of pain
CN102898315B (zh) *	2012-11-05	2015-01-28	上海毕得医药科技有限公司	3-乙炔基-4-氟苯胺的制备方法
EP3038623A4 (fr)	2013-09-09	2017-04-19	Melinta Therapeutics, Inc.	Composés antimicrobiens et procédés de fabrication et méthodes d'utilisation de ceux-ci
KR20160070066A (ko)	2013-09-09	2016-06-17	멜린타 테라퓨틱스, 인크.	항균 화합물, 및 이의 제조 방법 및 이용 방법
CA2979342A1 (fr)	2015-03-11	2016-09-15	Melinta Therapeutics, Inc.	Composes antimicrobiens et procedes de fabrication et d'utilisation de ceux-ci
EP3386983A1 (fr) *	2015-12-10	2018-10-17	Pfizer Limited	Dérivés 4-(biphényl-3-yl)-1h-pyrazolo[3,4-c]pyridazine de formule (i) utilisés comme modulateurs de récepteur gaba pour le traitement de l'épilepsie et de la douleur
WO2017129801A1 (fr)	2016-01-27	2017-08-03	Universität Zürich	Utilisation de modulateurs des récepteurs gabaa pour le traitement des démangeaisons
WO2017193016A1 (fr)	2016-05-06	2017-11-09	Melinta Therapeutics, Inc.	Antimicrobiens et leurs procédés de préparation et d'utilisation
BR112020021104A2 (pt) *	2018-04-18	2021-02-23	Neurocycle Therapeutics, Inc	compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185446A (en) *	1990-09-04	1993-02-09	Neurogen Corporation	Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
BR9608056A (pt) *	1995-04-21	1999-11-30	Neurosearch As	Compostos de benzimidazol, composições farmacêuticas contendo os compostos e sua utilização.
PA8535601A1 (es) *	2000-12-21	2002-11-28	Pfizer	Derivados benzimidazol y piridilimidazol como ligandos para gabaa

2002
- 2002-03-12 TW TW091104588A patent/TWI248936B/zh active
- 2002-03-19 DE DE60205101T patent/DE60205101T2/de not_active Expired - Lifetime
- 2002-03-19 HU HU0303630A patent/HUP0303630A3/hu unknown
- 2002-03-19 PE PE2002000211A patent/PE20020970A1/es not_active Application Discontinuation
- 2002-03-19 EE EEP200300455A patent/EE200300455A/xx unknown
- 2002-03-19 PL PL02363804A patent/PL363804A1/xx not_active Application Discontinuation
- 2002-03-19 MX MXPA03008572A patent/MXPA03008572A/es unknown
- 2002-03-19 ES ES02706976T patent/ES2244752T3/es not_active Expired - Lifetime
- 2002-03-19 AT AT02706976T patent/ATE299882T1/de not_active IP Right Cessation
- 2002-03-19 IL IL15764102A patent/IL157641A0/xx unknown
- 2002-03-19 KR KR10-2003-7012252A patent/KR20030083001A/ko not_active Withdrawn
- 2002-03-19 CN CNB028070577A patent/CN1294133C/zh not_active Expired - Fee Related
- 2002-03-19 SK SK1167-2003A patent/SK11672003A3/sk not_active Application Discontinuation
- 2002-03-19 CA CA2461426A patent/CA2461426C/fr not_active Expired - Fee Related
- 2002-03-19 EP EP02706976A patent/EP1381606B1/fr not_active Expired - Lifetime
- 2002-03-19 CZ CZ20032539A patent/CZ20032539A3/cs unknown
- 2002-03-19 WO PCT/GB2002/001352 patent/WO2002074773A1/fr not_active Ceased
- 2002-03-19 WO PCT/GB2002/001351 patent/WO2002074772A1/fr not_active Ceased
- 2002-03-19 JP JP2002573781A patent/JP4409174B2/ja not_active Expired - Fee Related
- 2002-03-19 BR BR0207994-1A patent/BR0207994A/pt not_active IP Right Cessation
- 2002-03-19 AU AU2002241138A patent/AU2002241138B2/en not_active Ceased
- 2002-03-19 NZ NZ527901A patent/NZ527901A/en unknown
- 2002-03-19 EA EA200301037A patent/EA006234B1/ru not_active IP Right Cessation
2003
- 2003-09-09 BG BG108166A patent/BG108166A/xx unknown
- 2003-09-19 NO NO20034170A patent/NO20034170L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1294133C (zh)	2007-01-10
CA2461426C (fr)	2010-08-03
NO20034170D0 (no)	2003-09-19
EA006234B1 (ru)	2005-10-27
IL157641A0 (en)	2004-03-28
JP2004523584A (ja)	2004-08-05
BR0207994A (pt)	2004-03-02
HUP0303630A3 (en)	2005-06-28
TWI248936B (en)	2006-02-11
NO20034170L (no)	2003-11-19
DE60205101D1 (de)	2005-08-25
EP1381606B1 (fr)	2005-07-20
JP4409174B2 (ja)	2010-02-03
EP1381606A1 (fr)	2004-01-21
MXPA03008572A (es)	2003-12-08
ATE299882T1 (de)	2005-08-15
EA200301037A1 (ru)	2004-04-29
CZ20032539A3 (en)	2004-03-17
SK11672003A3 (sk)	2004-05-04
CA2461426A1 (fr)	2002-09-26
AU2002241138B2 (en)	2007-09-20
DE60205101T2 (de)	2006-05-24
HUP0303630A2 (hu)	2004-03-01
WO2002074772A1 (fr)	2002-09-26
CN1498218A (zh)	2004-05-19
PE20020970A1 (es)	2002-11-01
NZ527901A (en)	2005-09-30
PL363804A1 (en)	2004-11-29
ES2244752T3 (es)	2005-12-16
KR20030083001A (ko)	2003-10-23
WO2002074773A1 (fr)	2002-09-26
EE200300455A (et)	2003-12-15

Publication	Publication Date	Title
BG108166A (en)	2004-09-30	Imidazo-pyrimidine derivatives as liigands for gaba receptors
AU1253002A (en)	2002-05-21	Imidazo-triazine derivatives as ligands for gaba receptors
WO2001038326A3 (fr)	2002-05-10	Derives d'imidazo-pyridine utilises comme ligands pour recepteurs de gaba
ATE310002T1 (de)	2005-12-15	Imidazotriazin-derivate als gaba-rezeptor- liganden
GB0212048D0 (en)	2002-07-03	Therapeutic agents
DE60214532D1 (de)	2006-10-19	Imidazopyrimidin-derivate als liganden für gaba-rezeptoren
ATE335741T1 (de)	2006-09-15	8-fluorimidazo(1,2-a)pyridin derivative als liganden für gaba rezeptoren
ATE284403T1 (de)	2004-12-15	Triazolopyridazinderivate als liganden für gaba- rezeptoren
EA199900164A1 (ru)	2000-04-24	Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк
DE60006260D1 (de)	2003-12-04	Imidazotriazinderivate als gaba rezeptor-liganden
ATE255109T1 (de)	2003-12-15	Imidazopyridinderivate als gaba rezeptor liganden
ATE250062T1 (de)	2003-10-15	Triazolopiridazinederivate als gaba rezeptor- liganden
DE60325865D1 (de)	2009-03-05	Phenylpyridazin derivative als liganden für gaba-rezeptoren
AU3546101A (en)	2001-08-20	Phosphor, arsenic and antimony compounds based upon diaryl-anellated bicyclo'2.2.n! parent substances and catalysts containing same
CA2257222A1 (fr)	1997-12-11	Derives d'amides
JO2312B1 (en)	2005-09-12	Imidazo-pyrimidine derivatives as associative groups of JABA receptors
MXPA02003639A (es)	2004-11-12	Proceso nuevo para la sintesis de (3as)-5, 5-dioxo-2, 3, 3a-4- tetrahidro-1h-pirrolo[2, 1c][1, 2, 4] benzotiadiazina.
PE44299A1 (es)	1999-05-06	Derivados sustituidos de triazolo-piridacina como ligandos para receptores gaba
WO2001080719A3 (fr)	2002-03-28	Methodes et compositions permettant de diagnostiquer la schizophrenie
CO5050329A1 (es)	2001-06-27	Nuevos derivados de tetrahidroisoquinoleina y procedimientos para su preparacion
DK1419167T3 (da)	2005-06-13	1-(2,5'-anhydro-lyxofuranosyl) thyminer til syntese af radiomarkerede fluor-3 doxynucleotider
WO2001080716A3 (fr)	2002-02-28	Methodes et compositions permettant de diagnostiquer la schizophrenie